A study by an international research group identified 15 novel biomarkers that are linked to late-onset dementias. These biomarkers are proteins, which predict cognitive decline and subsequent increased risk of dementia already 20 years before the disease onset.
The proteins are related to immune system dysfunction, blood-brain-barrier dysfunction, vascular pathologies, and central insulin resistance. Six of these proteins can be modified with currently available medications prescribed for conditions other than dementia.
“These findings provide novel avenues for further studies to examine whether drugs targeting these proteins could prevent or delay the development of dementia”, says lead author Joni Lindbohm MD, PhD from the University College London and University of Helsinki.
The results of the study have been published in the Alzheimer’s & Dementia: The Journal of the Alzheimer's Association.
New methods enable advances in dementia research
Amyloid beta and tau proteins have dominated pathophysiological research on dementia etiology, but to date prevention and treatment trials targeting these biomarkers have been unsuccessful. This has motivated researches to search also other potential mechanisms that could predispose to dementia. Recent development of scalable platforms has made it possible to analyze a wide range of circulating proteins, which may reveal novel biological processes linked to dementias.
In this study the authors were able to analyze proteins with novel large-scale protein panel from stored blood samples of the British Whitehall II and US Atherosclerosis Risk in Communities (ARIC) study collected 20 years ago. Using a panel of 5,000 proteins measured from plasma, the researchers identified proteins that predicted cognitive decline in 5-yearly screenings and subsequent onset of clinical dementia. The 15 proteins predicted dementia in both the British and US cohorts.
Further research will provide more information to find drug targets
“This new study is the first step in our 5-year Wellcome Trust funded research programme. We will next examine whether the identified proteins have a causal association with dementia, and whether they are likely to be modifiable, and druggable”, tells one of the authors, Professor Mika Kivimäki, Director of the Whitehall II study at University College London.
The ultimate aim of the research programme is to identify novel drug targets for dementia prevention.
Dementia rates and related cost are increasing
The global number of individuals living with dementia is approximately 45 million and the number is projected to two or three times higher in 2050. In USA the annual cost of care for those living with dementia have increased 35% since 2015 and are nearly one billion annually. It is the fifth leading cause of death globally and currently no cure for dementia causing diseases exist.
Dr. Joni Lindbohm, University of Helsinki, phone +358 40 753 8104, email: email@example.com
Professor Mika Kivimäki, University College London, UK, email: firstname.lastname@example.org
Original publication: Lindbohm JV, Mars N, Walker KA, Singh-Manoux A, Livingston G, Brunner EJ, Sipilä PN, Saksela K, Ferrie JE, Lovering R, Williams SA, Hingorani AD, Gottesman RF, Zetterberg H, Kivimäki M. Plasma proteins, cognitive decline and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies Alzheimer’s & Dementia 6/2021. DOI: doi.org/10.1002/alz.12419.